Overview

• The SCIMITAR phase II trial found that SBRT delivered in five sessions post-prostatectomy is as safe as conventional multi-week radiation therapy.
• Patients who received SBRT experienced similar urinary, bowel, and sexual side effects compared to those undergoing traditional radiation, with no significant differences in quality of life after two years.
• MRI-guided SBRT further reduced gastrointestinal and late genitourinary toxicity due to improved imaging precision and narrower treatment margins.
• Researchers emphasize that SBRT shortens treatment time, reduces healthcare costs, and may improve patient adherence to postoperative care.
• Long-term cancer control data from the ongoing EXCALIBUR trial and an upcoming SCIMITAR update are expected later this year to confirm SBRT’s efficacy in preventing recurrence.